Effect of Low-Dose Oral Minoxidil as Treatment of Permanent Chemotherapy-Induced Alopecia

  • End date
    Dec 14, 2022
  • participants needed
  • sponsor
    Northwestern University
Updated on 14 June 2022


An open label, pilot study involving the use of low dose oral minoxidil to treat permanent chemotherapy-induced alopecia.


Patients will be evaluated through clinical assessment, histology, quality of life assessment, and adverse event monitoring. The data gathered from this study will be used to determine the safety and efficacy of the treatment regimen for this subset of CIA patients. The oral minoxidil regimen will be considered effective if significant clinical regrowth, positive histological changes, and improved Quality of Life are reported after the onset of treatment.

Condition Permanent Chemotherapy-induced Alopecia
Treatment oral minoxidil
Clinical Study IdentifierNCT03831334
SponsorNorthwestern University
Last Modified on14 June 2022


Yes No Not Sure

Inclusion Criteria

Patients with a clinical diagnosis of permanent chemotherapy-induced alopecia who completed chemotherapy ≥ 6 months from the date of registration
Patients must be age ≥ 18 years
Females of child-bearing potential (FOCBP) and males must agree to use adequate contraception (e.g., hormonal contraceptives such as birth control pills, patch, intrauterine device; barrier contraception such as male/female condoms, diaphragm; male partner with vasectomy; abstinence) prior to study entry, for the duration of study participation, and for 30 days following completion of therapy
Should a female patient become pregnant or suspect she is pregnant while participating in
this study, she should inform her treating physician immediately
NOTE: A FOCBP is any woman (regardless of sexual orientation, having undergone a tubal
ligation, or remaining celibate by choice) who meets the following criteria: Has not
undergone a hysterectomy or bilateral oophorectomy Has had menses at any time in the
preceding 12 consecutive months (and therefore has not been naturally postmenopausal for >
FOCBP must have a negative urine or serum pregnancy test within 7 days prior to
registration on study
Patients must have the ability to understand and the willingness to sign a written
informed consent prior to registration in the study

Exclusion Criteria

Patients receiving any other investigational agents or using other alopecia treatments
in the past 3 months are not eligible
Patients currently undergoing systemic cancer treatment or within 6 months of
finishing chemotherapy are not eligible. Note: Patients receiving hormone modulators
are eligible
Patients who have pheochromocytoma, hypothyroidism, anemia, cutaneous GVHD
hypotension, or a history of hypersensitivity to any components of the drug
preparation are not eligible
Female patients who are pregnant or nursing are not eligible
Patients who have other forms of alopecia besides PCIA (with the exception of female
pattern Ludwig 1 alopecia) are not eligible
Patients on oral or injectable anticoagulants are not eligible to participate in the
optional punch biopsy
Patients who have an uncontrolled intercurrent illness including, but not limited to
any of the following, are not eligible: (Uncontrolled Hypertension, Ongoing or active
infection requiring systemic treatment, Symptomatic congestive heart failure, Unstable
angina pectoris, Cardiac arrhythmia, Pericardial effusion, Psychiatric illness/social
situations that would limit compliance with study requirements, Patients with any
other illness or condition that the treating investigator feels would interfere with
study compliance or would compromise the patient's safety or study endpoints.)
Patients currently taking guanethidine are not eligible. Patients may participate
after a 1-week washout period
Patients currently taking drugs that may enhance the hypotensive effect of minoxidil
are not eligible. Please contact study team regarding specific drug as washout period
as this will vary. Note: This includes: Alfuzosin, Amifostine, antipsychotic agents
Atazanavir, barbiturates, Benperidol, Brimonidine, Dapoxetine, Diazoxide, DULoxetine
Levodopa, Lormetazepam, Molsidomine, Naftopidil, Nicergoline, Nicorandil
Nitroprusside, Obinutuzumab, Pentoxifylline, phosphodiesterase 5 inhibitors
Probenecid, prostacyclin analogues, Quinagolide, and Valproate. If a patient is
currently taking any of these drugs, further evaluation will be required to determine
Patients who have any condition or situation which, in the investigator's opinion
puts the patient at significant risk, could confound the study results, or may
interfere significantly with the patient's participation in the study are not
Patients who are unable to communicate or cooperate with the investigator due to
language problems, poor mental development, or impaired cerebral function are not
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note